Actelion Ltd.

139 articles about Actelion Ltd.

• After Losing Out on Actelion, Deal-Hungry Sanofi Sets Eyes on This Massachusetts Biotech

  1/26/2017

• Actelion Release: Amid Takeover Talks With Johnson & Johnson, The Company's Hypertension Drug Flunks Key Phase III Test

  1/23/2017

• Sanofi Sees No Opening to Actelion Talks After Johnson & Johnson Steps Back in

  1/10/2017

• This is Why Actelion Canceled Its Appearance at the J.P. Morgan Conference Next Week

  1/6/2017

• Johnson & Johnson Deal Could Break Up Actelion Into Two Companies

  1/3/2017

• Battle for Actelion: Sanofi is Out, Johnson & Johnson is Back In

  12/22/2016

• Johnson & Johnson Confirms Exclusive Negotiations With Actelion

  12/21/2016

• Investors Grow Impatient With Sanofi and Actelion Over Acquisition and Possible Contingent Value Right

  12/21/2016

• Digging Deeper on Why Johnson & Johnson Abandoned the Actelion Acquisition

  12/15/2016

• Johnson & Johnson Walks and Sanofi Steps in to Woo Actelion

  12/14/2016

• Novartis AG CEO Plays Down Prospects For Actelion Bid

  12/7/2016

• Johnson & Johnson Woos Billionaire Doctors Who Don’t Need Cash In Actelion Bid

  12/6/2016

• Actelion Falls as the 'It's Complicated' Tag Gets Slapped on Relationship With Johnson & Johnson

  11/29/2016

• Trump Or Clinton? The U.S. Will Still Be Willing To Buy Good Pharmaceuticals, Says Actelion CEO

  10/24/2016

• Actelion Does Not See Significant CVS Hit To Opsumit Sales

  8/3/2016

• Actelion's Uptravi Received FDA Approval, to Enter U.S. Market in January

  12/23/2015

• Bay Area ZS Pharma Jumps on Merger Talks, Actelion Stock Drops

  9/18/2015

• Europe’s Biggest Biotech, Actelion, Offering $2.5 Billion to Buy U.S.-Based ZS Pharma

  9/14/2015

• Shire’s Plan B if Baxalta Bid Falls Through Includes Radius Health, Actelion, and Possibly Ariad

  9/9/2015

• Actelion Hits All Time High on Rumored $18.9 Billion Shire Bid

  6/9/2015